A Potent Inhibitor of Protein Sequestration by Expanded Triplet (CUG) Repeats that Shows Phenotypic Improvements in a Drosophila Model of Myotonic Dystrophy

Long M. Luu, Lien Nguyen, Shaohong Peng, Ju Yeon Lee, Hyang Yeon Lee, Chun Ho Wong, Paul Hergenrother, H. Y.Edwin Chan, Steven C Zimmerman

Research output: Contribution to journalArticle

Abstract

Myotonic dystrophy is the most common form of adult-onset muscular dystrophy, originating in a CTG repeat expansion in the DMPK gene. The expanded CUG transcript sequesters MBNL1, a key regulator of alternative splicing, leading to the misregulation of numerous pre-mRNAs. We report an RNA-targeted agent as a possible lead compound for the treatment of myotonic dystrophy type 1 (DM1) that reveals both the promise and challenges for this type of small-molecule approach. The agent is a potent inhibitor of the MBNL1–rCUG complex with an inhibition constant (Ki) of 25±8 nm, and is also relatively nontoxic to HeLa cells, able to dissolve nuclear foci, and correct the insulin receptor splicing defect in DM1 model cells. Moreover, treatment with this compound improves two separate disease phenotypes in a Drosophila model of DM1: adult external eye degeneration and larval crawling defect. However, the compound has a relatively low maximum tolerated dose in mice, and its cell uptake may be limited, providing insight into directions for future development.

Original languageEnglish (US)
Pages (from-to)1428-1435
Number of pages8
JournalChemMedChem
Volume11
Issue number13
DOIs
StatePublished - Jan 1 2016

Fingerprint

Trinucleotide Repeats
Myotonic Dystrophy
Drosophila
Lead compounds
Defects
Maximum Tolerated Dose
Muscular Dystrophies
RNA Precursors
Insulin Receptor
Alternative Splicing
HeLa Cells
Proteins
Genes
RNA
Phenotype
Molecules
Lead
Defect in Insulin Receptor
Direction compound

Keywords

  • Click chemistry
  • Drosophila model
  • Myotonic dystrophy
  • RNA recognition
  • RNA–protein inhibitor

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Organic Chemistry

Cite this

A Potent Inhibitor of Protein Sequestration by Expanded Triplet (CUG) Repeats that Shows Phenotypic Improvements in a Drosophila Model of Myotonic Dystrophy. / Luu, Long M.; Nguyen, Lien; Peng, Shaohong; Lee, Ju Yeon; Lee, Hyang Yeon; Wong, Chun Ho; Hergenrother, Paul; Chan, H. Y.Edwin; Zimmerman, Steven C.

In: ChemMedChem, Vol. 11, No. 13, 01.01.2016, p. 1428-1435.

Research output: Contribution to journalArticle

Luu, Long M. ; Nguyen, Lien ; Peng, Shaohong ; Lee, Ju Yeon ; Lee, Hyang Yeon ; Wong, Chun Ho ; Hergenrother, Paul ; Chan, H. Y.Edwin ; Zimmerman, Steven C. / A Potent Inhibitor of Protein Sequestration by Expanded Triplet (CUG) Repeats that Shows Phenotypic Improvements in a Drosophila Model of Myotonic Dystrophy. In: ChemMedChem. 2016 ; Vol. 11, No. 13. pp. 1428-1435.
@article{a150f7bbf23e4899be1d85990bfafaf7,
title = "A Potent Inhibitor of Protein Sequestration by Expanded Triplet (CUG) Repeats that Shows Phenotypic Improvements in a Drosophila Model of Myotonic Dystrophy",
abstract = "Myotonic dystrophy is the most common form of adult-onset muscular dystrophy, originating in a CTG repeat expansion in the DMPK gene. The expanded CUG transcript sequesters MBNL1, a key regulator of alternative splicing, leading to the misregulation of numerous pre-mRNAs. We report an RNA-targeted agent as a possible lead compound for the treatment of myotonic dystrophy type 1 (DM1) that reveals both the promise and challenges for this type of small-molecule approach. The agent is a potent inhibitor of the MBNL1–rCUG complex with an inhibition constant (Ki) of 25±8 nm, and is also relatively nontoxic to HeLa cells, able to dissolve nuclear foci, and correct the insulin receptor splicing defect in DM1 model cells. Moreover, treatment with this compound improves two separate disease phenotypes in a Drosophila model of DM1: adult external eye degeneration and larval crawling defect. However, the compound has a relatively low maximum tolerated dose in mice, and its cell uptake may be limited, providing insight into directions for future development.",
keywords = "Click chemistry, Drosophila model, Myotonic dystrophy, RNA recognition, RNA–protein inhibitor",
author = "Luu, {Long M.} and Lien Nguyen and Shaohong Peng and Lee, {Ju Yeon} and Lee, {Hyang Yeon} and Wong, {Chun Ho} and Paul Hergenrother and Chan, {H. Y.Edwin} and Zimmerman, {Steven C}",
year = "2016",
month = "1",
day = "1",
doi = "10.1002/cmdc.201600081",
language = "English (US)",
volume = "11",
pages = "1428--1435",
journal = "ChemMedChem",
issn = "1860-7179",
publisher = "John Wiley and Sons Ltd",
number = "13",

}

TY - JOUR

T1 - A Potent Inhibitor of Protein Sequestration by Expanded Triplet (CUG) Repeats that Shows Phenotypic Improvements in a Drosophila Model of Myotonic Dystrophy

AU - Luu, Long M.

AU - Nguyen, Lien

AU - Peng, Shaohong

AU - Lee, Ju Yeon

AU - Lee, Hyang Yeon

AU - Wong, Chun Ho

AU - Hergenrother, Paul

AU - Chan, H. Y.Edwin

AU - Zimmerman, Steven C

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Myotonic dystrophy is the most common form of adult-onset muscular dystrophy, originating in a CTG repeat expansion in the DMPK gene. The expanded CUG transcript sequesters MBNL1, a key regulator of alternative splicing, leading to the misregulation of numerous pre-mRNAs. We report an RNA-targeted agent as a possible lead compound for the treatment of myotonic dystrophy type 1 (DM1) that reveals both the promise and challenges for this type of small-molecule approach. The agent is a potent inhibitor of the MBNL1–rCUG complex with an inhibition constant (Ki) of 25±8 nm, and is also relatively nontoxic to HeLa cells, able to dissolve nuclear foci, and correct the insulin receptor splicing defect in DM1 model cells. Moreover, treatment with this compound improves two separate disease phenotypes in a Drosophila model of DM1: adult external eye degeneration and larval crawling defect. However, the compound has a relatively low maximum tolerated dose in mice, and its cell uptake may be limited, providing insight into directions for future development.

AB - Myotonic dystrophy is the most common form of adult-onset muscular dystrophy, originating in a CTG repeat expansion in the DMPK gene. The expanded CUG transcript sequesters MBNL1, a key regulator of alternative splicing, leading to the misregulation of numerous pre-mRNAs. We report an RNA-targeted agent as a possible lead compound for the treatment of myotonic dystrophy type 1 (DM1) that reveals both the promise and challenges for this type of small-molecule approach. The agent is a potent inhibitor of the MBNL1–rCUG complex with an inhibition constant (Ki) of 25±8 nm, and is also relatively nontoxic to HeLa cells, able to dissolve nuclear foci, and correct the insulin receptor splicing defect in DM1 model cells. Moreover, treatment with this compound improves two separate disease phenotypes in a Drosophila model of DM1: adult external eye degeneration and larval crawling defect. However, the compound has a relatively low maximum tolerated dose in mice, and its cell uptake may be limited, providing insight into directions for future development.

KW - Click chemistry

KW - Drosophila model

KW - Myotonic dystrophy

KW - RNA recognition

KW - RNA–protein inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84973349046&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973349046&partnerID=8YFLogxK

U2 - 10.1002/cmdc.201600081

DO - 10.1002/cmdc.201600081

M3 - Article

C2 - 27245480

AN - SCOPUS:84973349046

VL - 11

SP - 1428

EP - 1435

JO - ChemMedChem

JF - ChemMedChem

SN - 1860-7179

IS - 13

ER -